ÅǸ޴º
¹øÈ£ | ±¸ºÐ | Á¦¸ñ |
---|---|---|
203 | (±¹¿Ü)SCI | Different subtypes of epithelioid sarcoma and their clinical implication: long-term multi-institutional experience with a rare sarcoma |
202 | (±¹³»)KCI | È£»ê±¸Áõ°¡Áõ°ú PDGFRB À¯ÀüÀÚ Àç¹è¿À» º¸ÀÎ °ñ¼ö Á¾¾ç 1¿¹ |
201 | (±¹¿Ü)SCI | Normalization of Tumor Vessels by Tie2 Activationand Ang2 Inhibition Enhances Drug Delivery andProduces a Favorable Tumor Microenvironment |
200 | (±¹³»)SCOPUS | A case of atypical hemolytic uremic syndrome associated with the c.1273C£¾T mutation in the complement C3 gene |
199 | (±¹¿Ü)SCI | Predictors of general discomfort, limitations in activities of daily living and intention of a second donation in unrelated hematopoietic stem cell donation |
198 | (±¹¿Ü)SCI | Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations |
197 | (±¹¿Ü)SCI | Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial |
196 | (±¹³»)SCI | Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea |
195 | (±¹¿Ü)SCIE | Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma |
194 | (±¹¿Ü)SCIE | Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients |
Copyright ¨Ï chamc, All rights reserved.